RT Journal Article
SR Electronic
T1 Potent Antiviral Activities of Type I Interferons to SARS-CoV-2 Infection
JF bioRxiv
FD Cold Spring Harbor Laboratory
SP 2020.04.02.022764
DO 10.1101/2020.04.02.022764
A1 Emily Mantlo
A1 Natalya Bukreyeva
A1 Junki Maruyama
A1 Slobodan Paessler
A1 Cheng Huang
YR 2020
UL http://biorxiv.org/content/early/2020/04/05/2020.04.02.022764.abstract
AB The historical outbreak of COVID-19 disease not only constitutes a global public health crisis, but also has a devastating social and economic impact. The disease is caused by a newly identified coronavirus, Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2). There is an urgent need to identify antivirals to curtail the COVID-19 pandemic. Herein, we report the remarkable sensitivity of SARS-CoV-2 to recombinant human interferons α and β (IFNα/β). Treatment with IFN-α or IFN-β at a concentration of 50 international units (IU) per milliliter drastically reduce viral titers by 3.4 log or 4.5 log, respectively in Vero cells. The EC50 of IFN-α and IFN-β treatment is 1.35 IU/ml and 0.76 IU/ml, respectively, in Vero cells. These results suggested that SARS-CoV-2 is more sensitive to many other human pathogenic viruses, including the SARS-CoV. Overall, our results demonstrate the potent efficacy of human Type I IFN in suppressing SARS-CoV-2 replication, a finding which could inform future treatment options for COVID-19.